MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Earlier this year, Summit Therapeutics and Akeso unveiled new data on their PD-1/VEGF-A bispecific drug, ivonescimab, showing ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

And, in non-small cell lung cancer with specific EGFR mutations, MI Cancer Seek can be used with approved tyrosine kinase ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... bispecific antibody in combination with chemotherapy in solid ...